EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer

Robiya Joseph, Santosh K Dasari, Sujanitha Umamaheswaran, Lingegowda S Mangala, Emine Bayraktar, Cristian Rodriguez-Aguayo iD, Yutuan Wu, Nghi Nguyen, Reid T Powell, Mary Sobieski, Yuan Liu, Mark Seungwook Kim und 10 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25021278 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Robiya Joseph und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Histone Deacetylase Inhibitors, Receptor, EphA2. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometrial cancer is the most frequent malignant tumor of the female reproductive tract but lacks effective therapy. EphA2, a receptor tyrosine kinase, is overexpressed by various cancers including endometrial cancer and is associated with poor clinical outcomes. In preclinical models, EphA2-targeted drugs had modest efficacy. To discover potential synergistic partners for EphA2-targeted drugs, we performed a high-throughput drug screen and identified panobinostat, a histone deacetylase inhibitor, as a candidate. We hypothesized that combination therapy with an EphA2 inhibitor and panobinostat leads to synergistic cell death. Indeed, we found that the combination enhanced DNA damage, increased apoptosis, and decreased clonogenic survival in Ishikawa and Hec1A endometrial cancer cells and significantly reduced tumor burden in mouse models of endometrial carcinoma. Upon RNA sequencing, the combination was associated with downregulation of cell survival pathways, including senescence, cyclins, and cell cycle regulators. The Axl-PI3K-Akt-mTOR pathway was also decreased by combination therapy. Together, our results highlight EphA2 and histone deacetylase as promising therapeutic targets for endometrial cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsHistone Deacetylase InhibitorsReceptor, EphA2AnimalsFemaleHumansMiceApoptosisCell Line, TumorPanobinostatPhosphatidylinositol 3-KinasesMolecular Targeted Therapy

Stichwörter der Autor:innen

EphA2endometrial cancerhistone deacetylase

Substanzen

Histone Deacetylase InhibitorsPanobinostatPhosphatidylinositol 3-KinasesEPHA2 protein, humanReceptor, EphA2

Autor:innen und Institutionen

  • Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • UTHealth Houston Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • High-Throughput Research and Screening Center, Center for Translational Cancer Research, Texas A&M Health Science Center, Institute of Biosciences and Technology, Houston, TX 77030, USA.

ORCID-Profile: Cristian Rodriguez-Aguayo, Paola Amero, Shannon N Westin

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • NIH HHS
  • National Institutes of Health/National Cancer Institute
  • NIH
  • the American Cancer Society Research Professor Award, the Frank McGraw Memorial Chair in Cancer Research, the Dunwoody Fund, the Gordon Fund, and NIH-NCI
  • FWC Amy Krouse Rosenthal award
  • National Center for Advancing Translational Sciences

Zitieren

APA

Joseph, R., Dasari, S. K., Umamaheswaran, S., Mangala, L. S., Bayraktar, E., Rodriguez-Aguayo, C., Wu, Y., Nguyen, N., Powell, R. T., Sobieski, M., Liu, Y., Kim, M. S., Corvigno, S., Foster, K., Hanjra, P., Vu, T. C., Chowdhury, M. A., Amero, P., Stephan, C., …, & Sood, A. K. (2024). EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25021278

Vancouver

Joseph R, Dasari SK, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, et al. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25021278

BibTeX
@article{Joseph2024,
  author = {Joseph, Robiya and Dasari, Santosh K and Umamaheswaran, Sujanitha and Mangala, Lingegowda S and Bayraktar, Emine and Rodriguez-Aguayo, Cristian and Wu, Yutuan and Nguyen, Nghi and Powell, Reid T and Sobieski, Mary and Liu, Yuan and Kim, Mark Seungwook and Corvigno, Sara and Foster, Katherine and Hanjra, Pahul and Vu, Thanh Chung and Chowdhury, Mamur A and Amero, Paola and Stephan, Clifford and Lopez-Berestein, Gabriel and Westin, Shannon N and Sood, Anil K},
  title = {EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25021278}
}
Kostenlos starten →